Explore

Engineered Probiotic Bacteria Show Promise in Regulating Blood Sugar for Diabetes Management

Engineered Probiotic Bacteria Show Promise in Regulating Blood Sugar for Diabetes Management

Scientists from the Shanghai Academy of Natural Sciences (SANS) in China have developed an oral living drug, named GIFT, which utilizes engineered probiotic bacteria to detect and respond to high blood sugar levels. These bacteria, specifically a modified strain of Escherichia coli Nissle 1917 (EcN), are equipped with a built-in molecular glucose sensor. When ingested, the probiotics temporarily colonize the intestine. Upon detecting blood sugar levels rising above a normal threshold, the sensor activates therapeutic genes within the bacteria, prompting them to produce and release GLP-1, a hormone that stimulates insulin release to lower blood sugar. The system is designed to automatically cease hormone production once blood sugar returns to a healthy range. This innovative approach aims to provide precise, on-demand dosing, addressing a limitation of current diabetes injections like semaglutide, which deliver a constant, high dose and can lead to adverse reactions. Experiments in diabetic mice showed sign...

Pfizer’s COVID-19 Vaccine Required a Complex Network of Global Suppliers

Pfizer’s COVID-19 Vaccine Required a Complex Network of Global Suppliers

The production of the Pfizer-BioNTech COVID-19 vaccine was an unprecedented undertaking, characterized by its speed, scale, and global complexity. ...

Team Novo Nordisk Cyclists Demonstrate Athletic Prowess While Managing Type 1 Diabetes

Team Novo Nordisk Cyclists Demonstrate Athletic Prowess While Managing Type 1 Diabetes

Team Novo Nordisk Cyclists Demonstrate Athletic Prowess While Managing Type 1 Diabetes

FDA Clears New Blood Test for Alzheimer's Disease Diagnosis

FDA Clears New Blood Test for Alzheimer's Disease Diagnosis

The U.S. Food and Drug Administration (FDA) has cleared a new blood test, PrecivityAD2, for marketing. Developed by C2N Diagnostics, a startup from Washington University in St. Louis, this test aims to aid in the diagnosis of Alzheimer's disease. The test utilizes high-resolution mass spectrometry to quantitatively measure biomarkers associated with Alzheimer's, specifically the ratio levels of amyloid (Aβ42 and 40) and two forms of tau protein (p-tau217 and total tau217) in the blood. This method offers a less invasive alternative to cerebrospinal fluid testing, which typically involves a lumbar puncture or spinal tap. The fundamental technology behind PrecivityAD2 was initially developed by a Washington University Medicine team co-led by Randall J. Bateman, MD, and David M. Holtzman, MD, who also co-founded C2N Diagnostics nearly two decades ago. The test is designed to detect the presence of brain amyloid plaques, a key pathological feature of Alzheimer's disease.

Enveda's Experimental 'Exercise Pill' ENV-308 Shows Promise in First Human Trial, May Reduce Appetite and Mimic Physical Activity

Enveda's Experimental 'Exercise Pill' ENV-308 Shows Promise in First Human Trial, May Reduce Appetite and Mimic Physical Activity

Biotech company Enveda has announced encouraging results from the first clinical trial of its experimental drug, ENV-308, designed to curb appetite and replicate some of the body's effects of physical activity. The pill aims to harness the benefits of lactate phenylalanine (Lac-Phe), a molecule naturally produced by the body during vigorous exercise, which signals the brain to reduce the urge to eat. Scientists at Stanford discovered Lac-Phe in 2022. The Phase I clinical trial involved 88 healthy adults and primarily focused on assessing the drug's safety and tolerability. Participants tolerated ENV-308 across all tested doses, with the company reporting an "exceptional gastrointestinal safety profile." Early results also indicate that ENV-308 lowers leptin levels in both animals and humans, particularly in individuals with high initial levels of the hormone, which regulates hunger. This reduction in leptin suggests a potential role in weight management by decreasing hunger. Additionally, preclinical model...

Precise Bio Advances 3D-Printed Corneas to Address Global Shortage, Initiates U.S. FDA Application

Precise Bio Advances 3D-Printed Corneas to Address Global Shortage, Initiates U.S. FDA Application

Precise Bio, an Israeli regenerative medicine company with operations in North Carolina, is developing 3D-printed corneas to address the global shortage of transplantable corneal tissue. Last year, the company achieved a significant milestone by providing a patient with the first-ever corneal implant made solely from human cells grown in a lab. This technology utilizes tissue from a single donor cornea to generate enough cells to fabricate over 400 new corneas through sophisticated laboratory culture techniques and 3D bioprinting. The resulting transparent, layered structure mimics a healthy, natural cornea. An early-stage Phase I trial is currently underway in Israel to evaluate the safety of this technique in human patients. The company reports that the first patient, who had been legally blind for 14 years due to pseudophakic bullous keratopathy, has shown significant visual recovery, being able to read menus and subtitles within weeks of the transplant. Five patients have received the new transplants s...

Ultragenyx Receives FDA Approval for First Gene Therapy, Genglycos, for Glycogen Storage Disease Type Ia

Ultragenyx Receives FDA Approval for First Gene Therapy, Genglycos, for Glycogen Storage Disease Type Ia

Ultragenyx has received accelerated FDA approval for Genglycos (pariglasgene brecaparvovec-opnr), its first gene therapy, for the treatment of glycogen storage disease type Ia (GSDIa). This approval specifically targets adults and children over the age of 8 years who suffer from GSDIa, a rare genetic disorder caused by a deficiency of the G6PC enzyme, which is crucial for releasing glucose from the liver into the bloodstream. The condition leads to life-threatening hypoglycemia and other complications. Genglycos is a one-time AAV8 gene therapy designed to deliver a functional G6PC gene to the liver, aiming to restore the deficient enzyme and stabilize blood sugar levels during fasting. The approval follows a successful late-stage GlucoGene study, where the treatment significantly reduced daily cornstarch intake in patients compared to placebo. This marks Ultragenyx's fifth FDA approval and includes a valuable priority review voucher.

University of Miami Research Expands Stem Cell Donor Pool for Cancer Patients

University of Miami Research Expands Stem Cell Donor Pool for Cancer Patients

A Phase II clinical trial conducted by researchers at the University of Miami's Sylvester Comprehensive Cancer Center suggests that patients with blood cancers who lack a fully matched stem cell donor may still have effective transplant options. The study, published in Blood Advances, indicates that transplants from partially mismatched donors can lead to positive outcomes, potentially broadening the eligibility criteria for stem cell transplantation. Traditionally, a close match based on human leukocyte antigen (HLA) markers has been crucial to prevent graft-versus-host disease (GvHD), where donor immune cells attack the recipient's tissues. However, the trial utilized post-transplant cyclophosphamide (PTCy), a treatment given shortly after transplantation, which selectively eliminates highly reactive donor immune cells while preserving others necessary for a new immune system. This approach promotes donor cell acceptance and reduces the risk of severe GvHD. The ACCESS trial, a multicenter study, enrolled...

Penn State Researchers Develop Bioprinting Technique for Bone Tissue Regeneration

Penn State Researchers Develop Bioprinting Technique for Bone Tissue Regeneration

An interdisciplinary team of engineers and chemists at Penn State has developed a novel bioprinting technique capable of regenerating bone tissue. This method involves 3D printing tiny clusters of living cells, known as spheroids, which are optimized to support bone tissue regeneration and facilitate the formation of new blood vessels. The researchers introduced specific genetic information (microRNA strands miR-148b and miR-210) into undifferentiated stem cells to spur bone growth and vascularization. These modified cells are then assembled into spheroids and precisely placed within a scaffold using aspiration-assisted bioprinting. Experiments in the lab and in mouse models confirmed that this technique not only aids bone healing but also promotes vascularization, a critical factor for supporting thick bone tissue. The team observed that a combination of microRNA strands led to more effective bone development and vascularization.

Health Systems Adopt AI Chatbots to Streamline Patient Record Analysis

Health Systems Adopt AI Chatbots to Streamline Patient Record Analysis

Health systems across the U.S. are increasingly implementing generative AI tools, such as ChatEHR, to search and synthesize extensive patient medical records. These chatbots are designed to help clinicians navigate the often-bloated electronic health records (EHRs) to find critical information. For instance, at Stanford, a physician utilized ChatEHR to uncover a patient's previous diagnosis of sarcomatoid squamous cell carcinoma from a different health system, which subsequently explained current lymph node findings that had stumped multiple pathologists. This adoption marks a significant shift from initial experimental phases to broader implementation of both homegrown and vendor-built AI solutions within healthcare. The primary goal is to improve efficiency in accessing patient data, which has become a major challenge due to the sheer volume of information in modern EHR systems. The utility of these tools extends beyond solving complex diagnostic mysteries, offering broader benefits in daily clinical pra...

GLP-1 Drugs Reshape U.S. Healthcare Landscape, Prompting Strategic Reset for Providers and Payers

GLP-1 Drugs Reshape U.S. Healthcare Landscape, Prompting Strategic Reset for Providers and Payers

GLP-1 weight-loss drugs are significantly altering the U.S. healthcare system, prompting a strategic reset for providers, insurers, and investors, according to a new Wells Fargo report. These drugs, which have seen a more than 140% increase in use from 2022 to 2024, are shifting the focus from treating obesity-related complications to prevention. This shift is evident in the 34.1% decline in metabolic bariatric surgery volumes during the same period. GLP-1s are also demonstrating the ability to prevent costly complications, such as reducing major adverse cardiovascular events by 20% in high-risk populations. The report indicates that while GLP-1s offer long-term health benefits and potential reductions in healthcare utilization, they present significant near-term drug costs for employers, payers, and Medicare. Employer health costs are projected to rise by 9.5% in 2027, partly due to these drugs.

UConn Researchers Explore Precision Medicine for Pancreatic Cancer with Encapsulate Inc.

UConn Researchers Explore Precision Medicine for Pancreatic Cancer with Encapsulate Inc.

A collaborative research study at UConn School of Medicine is exploring precision medicine for pancreatic cancer in partnership with Encapsulate Inc., a startup company in the UConn Technology Incubation Program (TIP). The study aims to rapidly identify the most effective chemotherapy, immunotherapy, or combination for individual pancreatic cancer patients. Researchers are testing Encapsulate's pioneering Biochip System, which can examine a patient's tumor tissue sample, replicate its cellular growth in the lab, and predict which agents will be most effective at stopping its progression. Currently, chemotherapy for pancreatic cancer is effective only 60% of the time, often requiring multiple drug trials to find an effective treatment, which can prolong the process. The Biochip system has previously shown success in predicting cancer clinical outcomes in a microgravity environment aboard the International Space Station, and UConn researchers are now working to confirm these predictive results on Earth.